Paschka, P., Müller, M. C., Merx, K., Kreil, S., Schoch, C., Lahaye, T., . . . Hochhaus, A. (2003). Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission. Leukemia, 17(9), . https://doi.org/10.1038/sj.leu.2403033
Chicago-Zitierstil (17. Ausg.)Paschka, Peter, et al. "Molecular Monitoring of Response to Imatinib (Glivec®) in CML Patients Pretreated with Interferon Alpha. Low Levels of Residual Disease Are Associated with Continuous Remission." Leukemia 17, no. 9 (2003). https://doi.org/10.1038/sj.leu.2403033.
MLA-Zitierstil (9. Ausg.)Paschka, Peter, et al. "Molecular Monitoring of Response to Imatinib (Glivec®) in CML Patients Pretreated with Interferon Alpha. Low Levels of Residual Disease Are Associated with Continuous Remission." Leukemia, vol. 17, no. 9, 2003, https://doi.org/10.1038/sj.leu.2403033.